Valeant Pharmaceuticals (VRX) to Acquire Salix (SLXP), Reports 4Q, Full Year Results

Shares of the Valeant Pharmaceuticals International Inc. (VRX) were trading up +16.09 or +9.29 percent to $189.35 per share in Monday’s premarket. The company announced on Sunday that it would be acquiring Salix Pharmaceuticals (SLXP) in a deal worth $14.5 billion. In addition, the Valeant reported its 2014 fourth quarter and full year results early Read the full article... Read the rest of Valeant Pharmaceuticals (VRX) to Acquire Salix (SLXP), Reports 4Q, Full Year Results at InvestorGuide.com .